In contrast, among 59 patients without CF-LVADs, the concordance rate was 67%. The most common reason for discordance was supratherapeutic aPTT (>100 s) despite a therapeutic anti-FXa level. In fact, of those patients with an aPTT >100 s, according to the anti-FXa assay only 9% were in the supratherapeutic range, whereas almost 90% were in the anti-FXa therapeutic range. Furthermore, there was a difference in concordance among the 2 CF-LVAD patient subgroups: among patients admitted for heparin bridging, the concordance rate was 36%, and in those admitted for suspected CF-LVAD thrombosis and/or hemolysis, the concordance rate was 16%.
The authors noted that INR $1.5 and serum lactate dehydrogenase levels $2.5 times the upper limit of normal were associated with higher rates of discordance.
How should we interpret these findings? A closer look at the data may provide some additional insights and perhaps simplify the results. If we consider both UFH therapeutic strata the authors selected (i.e., the low and high therapeutic ranges) as 1 wider therapeutic range, we will find that among patients who had a therapeutic aPTT of 45 to 100 s, 
